Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · medullo-epn-umap@date-based

BS_JTMXAMB7

Med · Medulloblastoma

7e53688b-b474-5eec-8575-47fe5189aa28

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
Med
cancer_type_detailed
—
subtype
Medulloblastoma
cancer_type
Med
subtype
Medulloblastoma
overall_survival_months
1.44
os_event
false
age_years
10.082
umap1_2d
-3.983333909
umap2_2d
-1.218617744
umap1_3d
-1.413594503
umap2_3d
2.150887166
umap3_3d
1.75426395
dataset
Med-CBTN

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.460
  • OXIDATIVE_PHOSPHORYLATION+0.430
  • UNFOLDED_PROTEIN_RESPONSE+0.430
  • MYC_TARGETS_V1+0.420
  • MTORC1_SIGNALING+0.400
  • BILE_ACID_METABOLISM+0.370
  • MYC_TARGETS_V2+0.360
  • ANDROGEN_RESPONSE+0.310
  • ADIPOGENESIS+0.290
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.280

Top 10 suppressed

  • MITOTIC_SPINDLE-0.240
  • TNFA_SIGNALING_VIA_NFKB-0.170
  • ALLOGRAFT_REJECTION-0.160
  • G2M_CHECKPOINT-0.160
  • TGF_BETA_SIGNALING-0.070
  • WNT_BETA_CATENIN_SIGNALING-0.070
  • KRAS_SIGNALING_DN-0.050
  • SPERMATOGENESIS-0.040
  • E2F_TARGETS-0.020
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.010

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR22247246
lung-landscapes@6
—cohortA40.802
2SRR6013485
lung-landscapes@6
—cohortA40.772
3TCGA-E9-A22B-01A-11R-A157-07
breast-umap@18
—C0.768
4f34c57ee-92a6-4e3b-acde-7fd631c42f87
colon-landscapes@1
——0.761
5SRR1516101
bladder-landscape@3
——0.749
6c119f5ef.864c.434b.b515.57c27c7ae949
lung-landscapes@6
—cohortA10.736
755009_S132
lung-landscapes@6
—cohortA40.735
86F4F72B3-E2B1-48DD-B9F4-C03AFCE79566
brain-umap@2
——0.735
9C3N-00574
lung-landscapes@6
—cohortA40.728
10BS_NRFQEQKP
brain-umap@2
low-grade glioma—0.728

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 40 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.460Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.430Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.430Idelalisib— uncovered
MYC_TARGETS_V10.420Inavolisib— uncovered
MTORC1_SIGNALING0.400Inavolisib— uncovered
BILE_ACID_METABOLISM0.370Inavolisib— uncovered
MYC_TARGETS_V20.360Idelalisib— uncovered
ANDROGEN_RESPONSE0.310Inavolisib— uncovered
ADIPOGENESIS0.290Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.280Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.280Inavolisib— uncovered
FATTY_ACID_METABOLISM0.260Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.240Remibrutinib— uncovered
GLYCOLYSIS0.240Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.220Idelalisib— uncovered
ANGIOGENESIS0.210Remibrutinib— uncovered
PEROXISOME0.210Idelalisib— uncovered
COAGULATION0.200Binimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.190Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.120Inavolisib— uncovered